Current advances in Hodgkin's lymphoma.

Authors:
Joseph Vadakara
Joseph Vadakara
Fox Chase Cancer Center
Philadelphia | United States
Benjamin Andrick
Benjamin Andrick
Center for Pharmacy Innovations and Outcomes

Chronic Dis Transl Med 2019 Mar 19;5(1):15-24. Epub 2019 Mar 19.

Department of Hematology and Oncology, Geisinger Medical Center, Danville, PA 17822, USA.

Hodgkin's lymphoma is a highly treatable malignancy. It has high cure rates yet there are many patients who relapse or are refractory to treatment. Traditionally, treatment has been with conventional chemotherapy; however, the development of brentuximab vedotin and immune checkpoint inhibitors has revolutionized the care of Hodgkin's lymphoma. This is a review of the current advances in the management of Hodgkin's lymphoma and a review of ongoing clinical trials in the field.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cdtm.2019.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450804PMC
March 2019

Publication Analysis

Top Keywords

hodgkin's lymphoma
16
lymphoma review
8
current advances
8
traditionally treatment
4
treatment conventional
4
conventional chemotherapy
4
treatment traditionally
4
advances management
4
inhibitors revolutionized
4
relapse refractory
4
refractory treatment
4
chemotherapy development
4
development brentuximab
4
immune checkpoint
4
revolutionized care
4
checkpoint inhibitors
4
care hodgkin's
4
vedotin immune
4
patients relapse
4
brentuximab vedotin
4

Similar Publications